Atlas FDA

ANTI-HBC IGM

FDA premarket approval P010053/S007 · decided 2011-05-12

Approval details

PMA number
P010053
Supplement
S007
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
ANTI-HBC IGM
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
Siemens Healthcare Diagnostics Products, Ltd.
Date received
2011-02-18
Decision date
2011-05-12
Days to decision
83 days
Decision code
APPR
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Llanberis
Statement
APPROVAL FOR INTRODUCTION OF A NEW INSTRUMENT MODEL, THE IMMULITE 2000 XPI ANALYZER, AS A NEW FAMILY MEMBER OF THE CURRENTLY APPROVED IMMULITE 2000 ANALYZER, TO BE USED WITH THE CURRENTLY APPROVED IMMULITE 2000 ANTI-HBC IGM ASSAY. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME IMMULITE 2000 XPI ANTI-HBC IGM ASSAY AND IS INDICATED FOR IN VITRO DIAGNOSTIC USE FOR THE LABORATORY DIAGNOSIS OF ACUTE OR RECENT (USUALLY WITHIN 6 MONTHS) HEPATITIS B VIRUS INFECTIONS IN CONJUNCTION WITH O

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
IMMULITE® 2000 BR-MA (K233946)Siemens Healthcare Diagnostics Products, Ltd.2024-03-13
IMMULITE/IMMULITE 1000 OM-MA, IMMULITE 2000 OM-MA (K213510)Siemens Healthcare Diagnostics Products, Ltd.2023-09-08
IMMULITE® 2000 Cortisol (K202826)Siemens Healthcare Diagnostics Products, Ltd.2021-01-15
IMMULITE/IMMULITE® 1000 Cortisol (K203270)Siemens Healthcare Diagnostics Products, Ltd.2021-01-15